Two distinct urokinase-serpin interactions regulate the initiation of cell surface-associated plasminogen activation

被引:28
作者
Schwartz, BS [1 ]
España, F
机构
[1] Univ Wisconsin, Dept Med, Madison, WI 53706 USA
[2] Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA
[3] Hosp La Fe, Ctr Invest, E-46009 Valencia, Spain
关键词
D O I
10.1074/jbc.274.21.15278
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Single-chain urokinase-type plasminogen activator (scu-PA) possesses enzymatic activity that increases by 2-3 orders of magnitude upon binding to its cellular cofactor, the u-PA receptor (u-PAR), hence activating an enzymatic cascade initially composed of zymogens. The present study demonstrates that plasminogen activator inhibitor type 3 (PAI-3) reversibly inhibits scu-PA in solution, maintaining the system "off." Because the scu-PA/PAT-3 interaction is reversible, cellular expression of u-PAR allows partitioning of scu-PA from PAI-3 to u-PAR with resultant expression of full enzymatic activity. PAI-3 that was originally complexed to scu-PA remains in solution, retaining its functional activity. Importantly, the scu-PA on cell surface u-PAR is protected from PAI-3 inhibition, remaining an effective activator in a PAI-rich environment. Plasmin formed as a result of scu-PA activity then cleaves scu-PA to the mature protease, two-chain u-PA (tcu-PA), which is efficiently and irreversibly inhibited by PAI-3 via the standard serpin mechanism, even on u-PAR. This data generates a new hypothesis which in contrast to the previous paradigm, holds that receptor bound scu-PA is the initiating enzyme and that tcu-PA is generated not to augment enzymatic activity but rather to allow for inhibition and therefore appropriate regulation of the process.
引用
收藏
页码:15278 / 15283
页数:6
相关论文
共 29 条
[1]  
Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO
[2]  
2-Z
[3]  
BACHMAN F, 1994, HEMOSTASIS THROMBOSI, P1605
[4]  
Bachmann F., 1994, HEMOSTASIS THROMBOSI, V3rd, P1592
[5]  
BRUCH M, 1988, J BIOL CHEM, V263, P16626
[6]   ACCESSIBILITY OF RECEPTOR-BOUND UROKINASE TO TYPE-1 PLASMINOGEN-ACTIVATOR INHIBITOR [J].
CUBELLIS, MV ;
ANDREASEN, P ;
RAGNO, P ;
MAYER, M ;
DANO, K ;
BLASI, F .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (13) :4828-4832
[7]   PLASMINOGEN - PURIFICATION FROM HUMAN PLASMA BY AFFINITY CHROMATOGRAPHY [J].
DEUTSCH, DG ;
MERTZ, ET .
SCIENCE, 1970, 170 (3962) :1095-+
[8]   PURIFICATION AND CHARACTERIZATION OF PLASMA PROTEIN-C INHIBITOR [J].
ESPANA, F ;
BERRETTINI, M ;
GRIFFIN, JH .
THROMBOSIS RESEARCH, 1989, 55 (03) :369-384
[9]  
ESPANA F, 1993, THROMB HAEMOSTASIS, V70, P989
[10]   THE RECEPTOR FOR UROKINASE TYPE PLASMINOGEN-ACTIVATOR POLARIZES EXPRESSION OF THE PROTEASE TO THE LEADING-EDGE OF MIGRATING MONOCYTES AND PROMOTES DEGRADATION OF ENZYME-INHIBITOR COMPLEXES [J].
ESTREICHER, A ;
MUHLHAUSER, J ;
CARPENTIER, JL ;
ORCI, L ;
VASSALLI, JD .
JOURNAL OF CELL BIOLOGY, 1990, 111 (02) :783-792